{"id":3459,"date":"2016-08-30T12:15:02","date_gmt":"2016-08-30T09:15:02","guid":{"rendered":"http:\/\/info.e-med.co.il\/prolia\/?p=3459"},"modified":"2024-01-24T13:19:15","modified_gmt":"2024-01-24T11:19:15","slug":"denosumab-or-zoledronic-acid-in-postmenopausal-women-with-osteoporosis-previously-treated-with-oral-bisphosphonates","status":"publish","type":"post","link":"https:\/\/info.e-med.co.il\/evenity\/2016\/08\/30\/denosumab-or-zoledronic-acid-in-postmenopausal-women-with-osteoporosis-previously-treated-with-oral-bisphosphonates\/","title":{"rendered":"Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates."},"content":{"rendered":"
\n

Abstract<\/h3>\n
\n

CONTEXT:<\/h4>\n

Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis.<\/p>\n

OBJECTIVE:<\/h4>\n

The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover.<\/p>\n

DESIGN AND SETTING:<\/h4>\n

This was an international, multicenter, randomized, double-blind trial.<\/p>\n

PARTICIPANTS:<\/h4>\n

A total of 643 postmenopausal women with osteoporosis previously treated with oral bisphosphonates participated in the study.<\/p>\n

INTERVENTIONS:<\/h4>\n

Subjects were randomized 1:1 to sc denosumab 60 mg every 6 months plus iv placebo once or ZOL 5 mg iv once plus sc placebo every 6 months for 12 months.<\/p>\n

MAIN OUTCOME MEASURES:<\/h4>\n

Changes in BMD and bone turnover markers were measured.<\/p>\n

RESULTS:<\/h4>\n

BMD change from baseline at month 12 was significantly greater with denosumab compared with ZOL at the lumbar spine (primary end point; 3.2% vs 1.1%; P < .0001), total hip (1.9% vs 0.6%; P < .0001), femoral neck (1.2% vs -0.1%; P < .0001), and one-third radius (0.6% vs 0.0%; P < .05). The median decrease from baseline was greater with denosumab than ZOL for serum C-telopeptide of type 1 collagen at all time points after day 10 and for serum procollagen type 1 N-terminal propeptide at month 1 and at all time points after month 3 (all P < .05). Median percentage changes from baseline in serum intact PTH were significantly greater at months 3 and 9 with denosumab compared with ZOL (all P < .05). Adverse events were similar between groups. Three events consistent with the definition of atypical femoral fracture were observed (two denosumab and one ZOL).<\/p>\n

CONCLUSIONS:<\/h4>\n

In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greater BMD increases at all measured skeletal sites and greater inhibition of bone remodeling compared with ZOL.<\/p>\n<\/div>\n<\/div>\n

Miller PD et al., J Clin Endocrinol Metab.\u00a02016 Aug;101(8):3163-70. doi: 10.1210\/jc.2016-1801. Epub 2016 Jun 6.<\/p>\n

\u05dc\u05d4\u05de\u05e9\u05da \u05e7\u05e8\u05d9\u05d0\u05d4<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Prolia Vs Aclasta:<\/p>\n","protected":false},"author":2,"featured_media":3571,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[7,3,4],"tags":[],"class_list":["post-3459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-en","category-research","category-updates-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t